-
NVCT Dashboard
- Financials
- Filings
-
Holdings
-
Transcripts
- ETFs
- Insider
- Institutional
- Shorts
Nuvectis Pharma (NVCT)
Company Profile
Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 17.17 mm | 17.17 mm | 17.17 mm | 17.17 mm | 17.17 mm | 17.17 mm |
Cash burn (monthly) | 315.67 k | 407.50 k | 1.45 mm | 1.69 mm | 801.33 k | 1.14 mm |
Cash used (since last report) | 1.42 mm | 1.83 mm | 6.52 mm | 7.58 mm | 3.60 mm | 5.10 mm |
Cash remaining | 15.75 mm | 15.34 mm | 10.65 mm | 9.59 mm | 13.57 mm | 12.07 mm |
Runway (months of cash) | 49.9 | 37.6 | 7.3 | 5.7 | 16.9 | 10.6 |
13F holders | Current |
---|---|
Total holders | 31 |
Opened positions | 5 |
Closed positions | 14 |
Increased positions | 8 |
Reduced positions | 12 |
13F shares | Current |
---|---|
Total value | 5.97 bn |
Total shares | 1.29 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 301.14 k | $1.89 bn |
Pontifax Management 4 G.P. | 288.87 k | $2.28 mm |
Baldwin Brothers | 174.13 k | $1.10 bn |
Geode Capital Management | 79.72 k | $501.48 mm |
Millennium Management | 68.50 k | $430.86 mm |
Iridian Asset Management | 55.38 k | $348.34 mm |
Gsa Capital Partners | 50.13 k | $315.00 k |
BlackRock | 49.55 k | $311.69 mm |
Marshall Wace | 42.81 k | $269.30 mm |
Two Sigma Investments | 26.79 k | $168.48 mm |
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
7 Feb 25 | Mosseri Marlio Charles | Common Stock | Buy | Acquire P | Yes | No | 5 | 240,000 | 1.20 mm | 2,884,121 |
2 Jan 25 | Bentsur Ron | Common Stock | Grant | Acquire A | No | No | 0 | 250,000 | 0.00 | 3,520,924 |
2 Jan 25 | Shay Shemesh | Common Stock | Grant | Acquire A | No | No | 0 | 150,000 | 0.00 | 1,643,068 |
2 Jan 25 | Enrique Poradosu | Common Stock | Grant | Acquire A | No | No | 0 | 150,000 | 0.00 | 1,656,319 |
2 Jan 25 | Michael J. Carson | Common Stock | Grant | Acquire A | No | No | 0 | 51,000 | 0.00 | 138,918 |